In this work we are interested in a mathematical model of the collective behavior of a fully connected network of finitely many neurons, when their number and when time go to infinity. We assume that every neuron follows a stochastic version of the Hodgkin-Huxley model, and that pairs of neurons interact through both electrical and chemical synapses, the global connectivity being of mean field type. When the leak conductance is strictly positive, we prove that if the initial voltages are uniformly bounded and the electrical interaction between neurons is strong enough, then, uniformly in the number of neurons, the whole system synchronizes exponentially fast as time goes to infinity, up to some error controlled by (and vanishing with) the channels noise level. Moreover, we prove that if the random initial condition is exchangeable, on every bounded time interval the propagation of chaos property for this system holds (regardless of the interaction intensities). Combining these results, we deduce that the nonlinear McKean-Vlasov equation describing an infinite network of such neurons concentrates, as time goes to infinity, around the dynamics of a single Hodgkin-Huxley neuron with chemical neurotransmitter channels. Our results are illustrated and complemented with numerical simulations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00285-019-01326-7 | DOI Listing |
Transplant Cell Ther
March 2025
IRCCS University Hospital of Bologna, Seràgnoli Institute of Hematology, Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Background: The safety and efficacy of allogeneic stem cell transplantation (allo-SCT) following anti-programmed cell death protein 1 (PD-1) therapy in participants with hematologic malignances is of high clinical interest.
Objective: To present outcomes in participants enrolled in 4 clinical trials who underwent allo-SCT within 2 years of their last dose of pembrolizumab therapy.
Study Design: This analysis included participants from the phase 1b KEYNOTE-013 study (n = 20), the phase 2 KEYNOTE-087 study (n = 31), the phase 2 KEYNOTE-170 study (n = 5), and the phase 3 KEYNOTE-204 study (n = 14).
J Immunother Cancer
March 2025
Stephenson Cancer Center, University of Oklahoma, Oklahoma City, Oklahoma, USA
Background: Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited.
Methods: This is an international multicenter retrospective study of patients with cancer and cardiac metastasis at baseline. Patients who had received ≥1 dose of ICI were included.
Orphanet J Rare Dis
March 2025
Centre de Référence Maladies Rares PRADORT (syndrome de PRADer-Willi et autres Obésités Rares avec Troubles du Comportement Alimentaire), Hôpital des Enfants, CHU Toulouse, Université Toulouse III Paul Sabatier, 330, Avenue de Grande Bretagne, TSA 70034, 31059, Toulouse Cedex 9, France.
Background: Oxytocin (OT) plays an important role in modulating behavior, social interactions and feeding. Prader-Willi syndrome (PWS), a rare genetic neurodevelopmental disorder, is a model of hypothalamic disorder including OT dysfunction. We previously showed that infants with PWS who had received an early short course (7 days) of intranasal OT treatment improved their oral and social skills.
View Article and Find Full Text PDFImmunotherapy
February 2025
Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA.
Aims: To demonstrate pharmacokinetic equivalence of CT‑P39 administered via auto-injector (CT‑P39 AI) and European Union-approved reference omalizumab via pre-filled syringe (EU-OMA PFS) in healthy Japanese adults.
Participants & Methods: This open-label, Phase 1 study randomized participants (1:1) to a single 150 mg/mL dose of CT‑P39 AI or EU-OMA PFS. The primary endpoint was pharmacokinetic equivalence per area under the concentration-time curve from time zero to infinity (AUC) and maximum serum concentration (C).
Sci Rep
February 2025
Center for Renewable Energy and Microgrids, Huanjiang Laboratory, Zhejiang University, Zhuji, 311816, Zhejiang, China.
In recent years, DC microgrids supplying constant power loads (CPLs) have attracted significant attention due to their impact on overall system stability, which is attributed to their electrical characteristics that exhibit negative incremental impedance. This paper examines a secondary control strategy aimed at ensuring accurate power sharing and voltage restoration within an islanded DC microgrid supplying a constant power load. The droop control function is typically used in the primary control layer to facilitate power sharing among distributed generators (DGs).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!